Category — Healthcare
The Economic Times reports that in a survey of drug making companies in India’s $17 billion pharmaceutical industry the top 20 of them are changing their conservative ways of marketing for newer technology ranging from scientific detailing to doctors to using newer algorithms for better insights into issues like patient compliance.
Mobile apps and social media will play a bigger role in this growth, the study that is part of a larger report on global digital marketing trends found. Marketing spends through digital platforms is estimated to shoot up nearly 50% in the next two years to touch $33 million, Bangalore-based market research firm Indegene‘s study shows.
Sun Pharma launched a mobile app called RespiTrack earlier this year to ensure patients with asthma adhere to treatment regimens; GlaxoSmithKline’s local unit says that at least 20%-30% of its customers are already in the digital world; and Abbott Healthcare has introduced several tools like Knowledge Genie, a heart and liver app, and another one for vertigo exercises. Some of these build on augmented and virtual reality to engage with both doctors and patients.
November 15, 2016 No Comments
Bangalore, India-based Forus Health, a medical devices startup, established its first wholly-owned subsidiary Forus Health Inc, in San Leandro, California.
The company hired Dr. Cliff Wright, formerly with Johnson & Johnson, Bausch + Lomb, as executive vice president for North America, and Armond T. Dantino, formerly with Johnson & Johnson and Germany-based Heidelberg Engineering, as senior director of sales and marketing for North American operations, reports the Economic Times.
Founded in 2010, Forus Health has deployed its flagship adult retinal imaging device, 3nethra classic, in 25 countries.The company is backed by Accel Partners, IDG Ventures and Asian Health Fund.
November 14, 2016 No Comments
During the India-U.K. Technology Summit inaugurated by Prime Ministers Theresa May of Britain and Prime Minister Narendra Modi of India, the Indo UK Institute of Health (IUIH) Medi-cities Program announced Johnson & Johnson India as its technology partner in Orthopedics.
Johnson & Johnson’s Medical division will provide advanced medical technology and education in the field of Orthopedics to 11 IUIH medcities that are being established in India by IUIH. The IUIH program is one of the world’s largest health care initiatives currently underway to establish 11 hospitals along with medical colleges, with a total bed capacity of 11,000 and a throughput of between 1,100 and 1,650 medical students per year, reports the Economic Times.
“As a broadly based healthcare company, we are privileged to be able to serve patients and healthcare professionals in India, by working together with the Indo UK Institutes of Health towards our common goal of improving access to quality healthcare,” said Sushobhan Dasgupta, managing director of Johnson & Johnson Medical India.
November 14, 2016 No Comments
Chicago, Illinois-based Abbott will set up an innovation and development center in Mumbai, India aimed at developing new drug formulations, new indications, dosing, packaging and other differentiated offerings to feed into its global branded generics business that clocked sales of $3.7 billion last year. The center will act as a “hub” and ship products to at least 30 countries that will further develop the products to suit local needs, reports the Economic Times.
Without divulging the amount the company will invest, Michael Warmuth, Executive VP, Established Pharmaceuticals division of Abbott said the proposed investments will double the company’s local scientific manpower. He described India as a “cornerstone of success” making specific reference as a “talent exporter” and how it helped Abbott gain a scientific edge in its other countries of operations.
Commenting on the overall regulatory and economic environment in India, Warmuth said the regulators are trying to do the right things but he maintained it would be good to see the environment a little more stable when making investment decisions. “Overall that does not really change our view on the market itself,” he added.
November 10, 2016 No Comments
Dabur’s FMCG business ended Q2 of 2016-17 with a volume growth of 4.5%. In an interview with Mint, Dabur India‘s vice-chairman Amit Burman, discussed his vision for the company.
Some quotes by Amit Burman made during the interview:
We have been selling Ayurvedic and natural products for more than 130 years. Our products are based on scientific research based on old Ayurvedic knowledge. With time, more people will turn to science-based Ayurveda from faith-based Ayurveda. Innovation and efficient communication will definitely help us in staying ahead in the curve.
The focus on international markets should increase. Our aim is to make Dabur a multinational from India. That’s the long-term goal we have been working on.
Hunger for acquisitions should grow. There’s a limit on how much you can grow organically. Mergers and acquisitions are the route for faster growth.
Healthcare is one area that would be very big in future. Everything, even food, should have a health focus. These are not new areas but enhanced focus on these will ensure faster growth.
November 5, 2016 No Comments